Plain-English translation of NCT04199741 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new diagnostic imaging approach called , which combines a radioactive tracer with a targeted antibody to help doctors find and locate small cell lung cancer and related tumors in your body. The imaging scan works by looking for a specific marker called DLL3 on cancer cells. Researchers want to understand how safe this new imaging method is and how your body processes it.
Small cell lung cancer is aggressive and hard to detect early. Current imaging scans don't always find all the tumors. This trial is exploring whether this new targeted imaging approach can detect cancer more effectively and help doctors plan better treatment.
You likely qualify if…
You likely don't qualify if…
If you join, you'll have the new imaging scan performed after receiving an injection of the radioactive tracer. The scan itself works like a standard PET/CT scan, taking about 1–2 hours. Some participants may need a small tissue biopsy to confirm their tumor has the DLL3 marker, though this may be waived depending on your scan results and what your doctor thinks is best. You'll also have blood work and follow-up visits so researchers can monitor your safety and how your body responds.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment target
~105 participants
Started
December 2019
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mark P Dunphy, DO
Memorial Sloan Kettering Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.